Lifeflo Gears up to Offer Cash O2 Product
Company’s three oxygen offerings include an over-the-counter retail option that delivers emergency oxygen without prescription.
- By David Kopf
- Apr 21, 2016
Oxygen product maker Lifeflo Inc. is about to debut three emergency and supplemental oxygen products using a new patent pending technology, with one of them being ideal for a retail offering.
Lifeflo recently showed the product at the Feb. 29-March 2 Medtrade Spring in Las Vegas where the new technology drew some attention, according to the Temecula, Calif.-based company’s CEO Dan Normand.
DME owners hovered around the booth like we were the queen bee,” Normand said. “I walked away from that knowing that we were on the right track, and knowing that we have to get this to market as quickly as we can and start building up the buzz.”
The three products in the Lifeflo is preparing to debut are:
- Lifeflo OTC Emergency Oxygen, an FDA-approved device designed to provide 6 liters a ,inute for 15 to 20 Minutes in emergency situations. No prescription is required and it has a three-year shelf life, which makes it enticing as a cash sales item.
- Lifeflo Rx2.0 Supplemental Oxygen, an FDA-approved device that provides 2 liters a miute for 45 to 60 Minutes. This product does require a physician’s prescription.
- Lifeflo Rx1.0 Newborn Oxygen, an FDA approved-device designed to provide .5 to 1 liter a minute for three to four hours for newborn babies in developing countries.
As a retail product, the Lifeflo OTC Emergency Oxygen acts as a life-saving product that DME providers can use to expand their revenues, Normand said
“We believe that carrying this technology gives HME providers an opportunity to market a simple and affordable technology,” he noted. “DME providers can sell this product without a prescription from the physician. People [at Medtrade] were shocked by that.”
For oxygen prescriptions, the Lifeflo Rx2.0 Supplemental Oxygen product amounts to two liters a minute for 45 minutes, which Normand characterized as “the only oxygen ‘pill’ that is available.”
David Kopf is the Publisher and Executive Editor of HME Business and DME Pharmacy magazines. Follow him on Twitter at @postacutenews.